Short Interest in Aptose Biosciences Inc. (NASDAQ:APTO) Increases By 1,012.9%

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) was the recipient of a significant increase in short interest in December. As of December 31st, there was short interest totalling 2,090,000 shares, an increase of 1,012.9% from the December 15th total of 187,800 shares. Based on an average daily volume of 6,360,000 shares, the short-interest ratio is presently 0.3 days. Currently, 3.7% of the company’s stock are short sold.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on APTO shares. StockNews.com initiated coverage on Aptose Biosciences in a report on Wednesday, January 8th. They set a “hold” rating on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $2.00 price objective on shares of Aptose Biosciences in a report on Friday, January 10th.

Aptose Biosciences Stock Performance

APTO traded up $0.00 on Wednesday, reaching $0.20. 297,946 shares of the company’s stock were exchanged, compared to its average volume of 1,077,562. Aptose Biosciences has a twelve month low of $0.13 and a twelve month high of $2.42. The company’s 50 day moving average is $0.24 and its 200-day moving average is $0.39. The company has a market cap of $12.23 million, a price-to-earnings ratio of -0.07 and a beta of 0.87.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp raised its position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 401,750 shares of the biotechnology company’s stock after purchasing an additional 167,282 shares during the quarter. Sigma Planning Corp owned about 2.22% of Aptose Biosciences worth $165,000 as of its most recent filing with the Securities and Exchange Commission. 26.62% of the stock is owned by institutional investors.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.